Theraclion Executes Strategy in First Half - Seite 2

R&D is the pillar of value creation

Successive improvements will be made to the system over the next few years, notably in robotics and artificial intelligence. Combining its real-time imaging and robotics capabilities, AI algorithms will automate certain tasks, speed up the procedure, and drastically simplify interactions between the doctor and SONOVEIN.

Partnerships with a dozen reference centers in Europe are continuing, contributing to the accelerated advancement of the technology.

First-half 2023 sales up 183%

Theraclion SA reported sales of €981 K for the first half of 2023, an increase of 183% compared with the first half of 2022. Theraclion is also maintaining strict control over its expenses.

System sales, at €597 K, were up 469%. Theraclion sold a latest-generation device to the University of Virginia as part of a clinical trial on breast cancer research. Approved by the FDA, this pilot study aims to evaluate the combined effects of high-intensity focused ultrasound (HIFU) and low-dose chemotherapy on the immune response in patients with early-stage breast cancer.

Additional revenues on previous sales were also recorded.

Sales of consumables rose by 65%, driven by a doubling of sales in the varicose vein indication. Theraclion has chosen to make SONOVEIN available to reference centers for the development of treatment protocols. These centers have the option of using SONOVEIN in their commercial practice, which generates revenue for Theraclion.

In summary, Martin Deterre, Chief Executive Officer of Theraclion, said, "Theraclion is intensifying its efforts on its clearly defined strategy: focusing its forces on the U.S. clinical study, building its partnership with Furui in China, and deploying transformative technological improvements for physicians and patients."

Sales /K€		S1 2023		S1 2022		Variation
System sales		597		105		+469%
Consumable sales		314		190